Regression of prostate cancer xenografts by RLIP76 depletion
- 15 March 2009
- journal article
- research article
- Published by Elsevier BV in Biochemical Pharmacology
- Vol. 77 (6), 1074-1083
- https://doi.org/10.1016/j.bcp.2008.11.013
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- RLIP76 in Defense of Radiation PoisoningInternational Journal of Radiation Oncology*Biology*Physics, 2008
- Cotargeting survival signaling pathways in cancerJCI Insight, 2008
- Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse modelJCI Insight, 2008
- Hsf-1 and POB1 Induce Drug Sensitivity and Apoptosis by Inhibiting Ralbp1Journal of Biological Chemistry, 2008
- Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1®Biochemical Pharmacology, 2008
- Celecoxib Inhibits Prostate Cancer Growth: Evidence of a Cyclooxygenase-2-Independent MechanismClinical Cancer Research, 2005
- Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): Studies in nude miceThe Prostate, 2003
- Cyclopropane-Containing Polyamine Analogues Are Efficient Growth Inhibitors of a Human Prostate Tumor Xenograft in Nude MiceJournal of Medicinal Chemistry, 2003
- Transport of glutathione conjugates and chemotherapeutic drugs by RLIP76 (RALBP1): A novel link between G‐protein and tyrosine kinase signaling and drug resistanceInternational Journal of Cancer, 2003
- Functional Modulation of ATPase of P-Glycoprotein by C219, a Monoclonal Antibody against P-GlycoproteinBiochemical and Biophysical Research Communications, 1997